Cyient DLM’s board has approved the unaudited financial results for Q3 2026 and the nine months ending December 31, 2025. The board has also approved a variation in the objects of the IPO funds, pending shareholder approval via postal ballot. A re-constitution of board committees was also authorized, including the Nomination and Remuneration, Audit, and Risk Management Committees. Meeting commenced at 01:45 P.M IST and concluded at 03:30 P.M IST.
Q3 2026 Financial Results Approved
The board of directors has approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025. These results have undergone a limited review report and are detailed in Annexure A. Key financial highlights will be available on the company’s website.
IPO Fund Object Variation
An alteration in the designated use of IPO funds has been sanctioned by the board. This variation is subject to the approval of the shareholders, which will be sought through a postal ballot.
Re-constitution of Board Committees
Several board committees have been re-constituted with changes in membership. Here is a summary:
Nomination and Remuneration Committee
Dr. Vanitha Datla remains as Chairperson, with Mr. Giridhar Aramane and Mr. B.V.R Mohan Reddy as members.
Audit Committee
Mr. Jehangir Ardeshir continues as Chairperson, with Mr. Murali Yadama, Dr. Ganesh Natarajan and Mr. Krishna Bodanapu as members.
Risk Management Committee
Mr. Jehangir Ardeshir will continue as Chairperson, with Mr. Murali Yadama, Dr. Ganesh Natarajan and Mr. Krishna Bodanapu as members.
Source: BSE
